1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014

Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Pleural Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Pleural Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Pleural Mesothelioma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Malignant Pleural Mesothelioma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Malignant Pleural Mesothelioma 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Malignant Pleural Mesothelioma Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Malignant Pleural Mesothelioma 32
Dec 20, 2013: MolMed expands in Russia the Phase II trial of NGR-hTNF for the first line maintenance treatment of pleural mesothelioma 32
Oct 28, 2013: Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma 32
Sep 10, 2013: Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in Patients with Mesothelioma 33
Aug 27, 2013: Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR Study in Mesothelioma 34
Mar 07, 2013: Oxford BioMedica Announces Initiation of Phase II Collaborative Study For TroVax In Malignant Pleural Mesothelioma 34
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
Eli Lilly and Company 36
Clinical Trial Overview of Eli Lilly and Company 36
Novartis AG 37
Clinical Trial Overview of Novartis AG 37
Verastem, Inc. 38
Clinical Trial Overview of Verastem, Inc. 38
MolMed S.p.A. 39
Clinical Trial Overview of MolMed S.p.A. 39
Merck and Co., Inc. 40
Clinical Trial Overview of Merck and Co., Inc. 40
Virttu Biologics Limited 41
Clinical Trial Overview of Virttu Biologics Limited 41
Polaris Group 42
Clinical Trial Overview of Polaris Group 42
Boehringer Ingelheim GmbH 43
Clinical Trial Overview of Boehringer Ingelheim GmbH 43
AstraZeneca PLC 44
Clinical Trial Overview of AstraZeneca PLC 44
Aduro BioTech, Inc. 45
Clinical Trial Overview of Aduro BioTech, Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
Memorial Sloan Kettering Cancer Center 48
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 48
European Organization for Research and Treatment of Cancer 49
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 49
Istituto Clinico Humanitas 50
Clinical Trial Overview of Istituto Clinico Humanitas 50
The University of Texas M. D. Anderson Cancer Center 51
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 51
Columbia University 52
Clinical Trial Overview of Columbia University 52
Abramson Cancer Center 53
Clinical Trial Overview of Abramson Cancer Center 53
Hyogo College Of Medicine 54
Clinical Trial Overview of Hyogo College Of Medicine 54
University Health Network 55
Clinical Trial Overview of University Health Network 55
Five Key Clinical Profiles 56
Appendix 142
Abbreviations 142
Definitions 142
Research Methodology 143
Secondary Research 143
About GlobalData 144
Contact Us 144
Disclaimer 144
Source 145

List of Tables
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2014* 7
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Malignant Pleural Mesothelioma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Malignant Pleural Mesothelioma Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Malignant Pleural Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 36
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 37
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Verastem, Inc., 2014* 38
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by MolMed S.p.A., 2014* 39
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 40
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Virttu Biologics Limited, 2014* 41
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Polaris Group, 2014* 42
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Boehringer Ingelheim GmbH, 2014* 43
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 44
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Aduro BioTech, Inc., 2014* 45
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 48
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 49
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Istituto Clinico Humanitas, 2014* 50
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 51
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2014* 52
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Abramson Cancer Center, 2014* 53
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Hyogo College Of Medicine, 2014* 54
Malignant Pleural Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 55

List of Figures
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Malignant Pleural Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 143

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.